The rate of ABL2 mutation was 7% in HNSCs, and we suppose that the mutation resulted in the aberrant methylation or deregulation of ABL2. ABL2 is only the target for one kind of drug at present, and ABL2 may serve as a drug target for more drugs in the future, such as anti-tumor drugs. The gene discussed is ABL2; the disease is neoplasm.